Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

Introduction: Checkpoint inhibitors, including the CTLA-4 blocking antibody ipilimumab, have become the new standard therapy for many metastatic cancers. Development of anti-drug antibodies (ADAs) after treatment with other biopharmaceuticals has been thoroughly described, but the induction of ADAs...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Kverneland, Anders H., Enevold, Christian, Donia, Marco, Bastholt, Lars, Svane, Inge Marie, Nielsen, Claus H.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927482/
https://ncbi.nlm.nih.gov/pubmed/29721387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1424674
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados